National Cancer Institute (NCI): Disease Progression trials
The registry lists 11 Disease Progression studies with National Cancer Institute (NCI) as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 2Phase 2 5No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate CancerRecruitingNCT04692675Not applicable
- Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord EpendymomaTerminatedNCT03727841Phase 2Results posted
- TRC105 for Recurrent GlioblastomaTerminatedNCT01778530Phase 2Results posted
- A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade GliomasCompletedNCT00995007Phase 2Results posted
- Bevacizumab and Irinotecan to Treat Brain TumorsTerminatedNCT00393094Phase 2Results posted
- Tamoxifen and Bortezomib to Treat Recurrent Brain TumorsCompletedNCT00108069Phase 2Results posted
- HLA-B35 Alleles and AIDSWithdrawnNCT00340223
- Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial CancerCompletedNCT00339651
- Markers for Breast CancerCompletedNCT00339248
- ZD6474 to Treat Advanced Brain Cancer in PatientsCompletedNCT00272350Phase 1
- Enzastaurin to Treat Recurrent Brain TumorTerminatedNCT00108056Phase 1